Table of Contents

Genetic Toxicology Studies - Study Design of In Vitro Mammalian Cell Micronucleus Test (Human Peripheral Blood Lymphocytes-HPBL) (OECD 487)

The in vitro micronucleus test using human peripheral blood lymphocytes (HPBL) is a valuable genotoxicity assay outlined in the OECD 487 guideline. It assesses the ability of a substance to induce chromosomal damage in cultured human lymphocytes, providing insights into potential human health risks.

Objectives:

Determine if a test substance can induce the formation of micronuclei (small extranuclear chromatin fragments) in cultured HPBLs.
Evaluate the dose-response relationship for micronucleus induction.
Classify the substance according to its genotoxic potential for regulatory purposes.

Test System:

Cell source: Human peripheral blood lymphocytes (HPBLs) are isolated from healthy volunteer donors (typically young, non-smokers with no recent exposure to genotoxic agents).
Culture conditions: HPBLs are cultured in suitable media under controlled conditions, often stimulated with mitogens like phytohaemagglutinin (PHA) to induce cell division.

Exposure and treatment:

HPBL cultures are exposed to the test substance at various concentrations, both with and without metabolic activation using S9 mix.
Exposure times typically range from 24 to 48 hours, followed by a recovery period to allow for micronucleus formation in daughter cells.

Cytotoxicity assessment:

Cell viability and mitotic index are assessed to determine the cytotoxicity of the test substance at different doses.

Micronucleus scoring:

After exposure and a recovery period, cells are harvested and stained to visualize nuclei and micronuclei.
Microscope analysis is conducted to score the number of cells with micronuclei at each dose level.
A defined number of cells (typically 1000 per dose level) are scored for the presence of micronuclei.
Micronucleus frequency is calculated as the percentage of cells containing micronuclei.

Endpoints:

Frequency of micronucleated cells at different dose levels.
Dose-response relationship for micronucleus induction.
Proliferation index (percentage of dividing cells) as a measure of cytotoxicity.
Nuclear division index (NDI) to assess cell cycle kinetics.
Micronucleus index (ratio of micronucleated cells to total cells).
Classification of the test substance according to OECD 487 criteria (e.g., genotoxic, non-genotoxic).

Benefits:

Provides information on clastogenic and aneugenic effects in human cells, potentially improving its relevance to human health risk assessment.
Relatively rapid and cost-effective compared to in vivo studies.
Can be adapted to assess a wide range of chemicals.

Limitations:

May be more susceptible to inter-individual variability due to donor differences.
Limited metabolic activation capacity compared to whole liver S9 mix.
Cannot detect all types of genetic damage (e.g., point mutations).

Additional Resources

OECD Test Guideline 487: https://www.oecd.org/publications/test-no-487-in-vitro-mammalian-cell-micronucleus-test-9789264264861-en.htm
Micronucleus Assay in Humans: Advantages and Limitations: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645216/
The In Vitro Micronucleus Assay Using Human Lymphocytes: A Review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505487/